Abstracts tagged "psoriatic arthritis and registries"

Abstract Number: 2605 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Lennart Jacobsson², Michael J. Nissen³, Eirik K Kristianslund⁴, Maria José Santos⁵, Kari Eklund⁶, Ziga Rotar⁷, Björn Gudbjornsson⁸, Fatos Onen⁹, Catalin Codreanu¹⁰, Ulf Lindström¹¹, Cem Gabay³, Tore Kvien⁴, Anabela Barcelos⁵, Kalle Aaltonen⁶, Matija Tomšič⁷, Thorvardur Love⁸, Gerçek Can⁹, Ruxandra Ionescu¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Karel Pavelka¹², Marleen van de Sande¹³, Irene van der Horst-Bruinsma¹⁴, Juan J. Gomez-Reino¹⁵, Carlos Sánchez-Piedra¹⁶, Gary J Macfarlane¹⁷, Florenzo Iannone¹⁸, Lise Hyldstrup¹, Niels Steen Krogh¹⁹, Mikkel Østergaard¹ and Merete Lund Hetland¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Gothenburg, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ⁸ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ⁹TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ¹⁰RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ¹¹ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Amsterdam, Netherlands, ¹⁴ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁵BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁶BIOBASADER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁷BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁸GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁹ZiteLab ApS, Copenhagen, Denmark
Drug retention and response rates of TNFi treatment in 13,170 patients with psoriatic arthritis treated in routine care – pooled data from the EuroSpA Research…
Abstract Number: 2596 • 2018 ACR/ARHP Annual Meeting
Real-World Long-Term Effectiveness of Switching between Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register
Elsa Vieira-Sousa^1,2, Mónica Eusébio³, Pedro Ávila-Ribeiro^1,2, Nikita Khmelinskii^1,2, Ana Rita Machado^1,2, Teresa Martins-Rocha^4,5, Miguel Bernardes^4,5, Daniela Santos Faria⁶, Joana Leite Silva⁶, Helena Santos⁷, Cláudia Miguel⁷, Pedro Carvalho^8,9, Tiago Costa¹⁰, Lídia Teixeira¹¹, Tiago Meirinhos¹², Patrícia Nero¹³ and Maria José Santos^11,14, ¹Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, Lisboa, Portugal, ²Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisboa, Portugal, Lisboa, Portugal, ³Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, LIsboa, Portugal, ⁴Serviços de Reumatologia do Centro Hospitalar São João do Porto, Porto, Portugal, Porto, Portugal, ⁵Faculdade de Medicina da Universidade do Porto (FMUP), Porto, Portugal, Porto, Portugal, ⁶Serviço de Reumatologia da Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁷Instituto Português de Reumatologia Lisboa, Portugal, Lisboa, Portugal, ⁸Serviço de Reumatologia, Hospitais Universitários de Coimbra, Coimbra, Portugal, Coimbra, Portugal, ⁹Serviço de Reumatologia, Centro Hospitalar e Universitário do Algarve, Faro, Portugal, Faro, Portugal, ¹⁰Serviço de Reumatologia do Hospital Egas Moniz, Lisboa, Portugal, Lisboa, Portugal, ¹¹Serviço de Reumatologia do Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ¹²Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, Aveiro, Portugal, ¹³Hospital CUF Descobertas, Lisboa, Portugal, Lisboa, Portugal, ¹⁴Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, Lisboa, Portugal
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) lead to a dramatic improvement in the management of psoriatic arthritis (PsA). Nevertheless, a significant proportion of patients…
Abstract Number: 678 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Disease Activity in Psoriatic Arthritis Patients with Dactylitis or Enthesitis: Results from Corrona Registry
Philip J. Mease¹, Chitra Karki², Carol J. Etzel^2,3, Arthur Kavanaugh⁴, Christopher T. Ritchlin⁵, Wendi Malley², Vivian Herrera⁶, Jacqueline B. Palmer⁶ and Jeffrey D. Greenberg^2,7, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³The University of Texas MD Anderson Cancer Center, Houston, TX, ⁴University of California San Diego, La Jolla, CA, ⁵Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷New York University School of Medicine, Millburn, NJ
Background/Purpose: Psoriatic arthritis (PsA) exhibits considerable heterogeneity in its presentation and course, which contributes to the complexity of diagnosis and assessment. Enthesitis, inflammation at the…
Abstract Number: 3118 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Disease Outcomes in Psoriatic Arthritis Patients By Extent of Body Surface Area Affected By Psoriasis: Results from Corrona Registry
Philip J. Mease^1,2,3,4, Chitra Karki⁵, Carol J. Etzel^5,6, Arthur Kavanaugh⁷, Christopher T. Ritchlin⁸, Wendi Malley⁵, Vivian Herrera⁹, Jacqueline B. Palmer⁹ and Jeffrey D. Greenberg^5,10, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Seattle Rheumatology Associates, Seattle, WA, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Clinical Professor, University of Washington School of Medicine, Seattle, WA, ⁵Corrona, LLC, Southborough, MA, ⁶University of Texas M.D. Anderson Cancer Center, Houston, TX, ⁷University of California San Diego, La Jolla, CA, ⁸Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰NYU School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a type of inflammatory arthritis that is commonly comorbid with the skin condition, psoriasis. A major contributor to the severity…
Abstract Number: 328 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population
Philip J. Mease¹, Emily Edson-Heredia², Katherine C. Saunders³, Catherine L. Shuler², Baojin Zhu², Monica Chaudhari⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Eli Lilly and Company, Indianapolis, IN, ³Corrona, LLC., Southborough, MA, ⁴Axio Research LLC, Seattle, WA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY
Background/Purpose: The use of biologic therapy in psoriatic arthritis (PsA) has altered the disease course and has been shown to reduce disease activity. Data comparing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].